Germany launch via forhims.de (men's weight management), riding on the footprint from the 2025 Zava acquisition
Hims officially launched in Germany on 20 Oct (company release) with forhims.de, starting with men's weight management. Consultations are online, and prescriptions are decided by EU-licensed doctors. Patients who need in-person care are referred to their own physician. The company frames the service as a supplement to the existing system, not a replacement.
Read more
The logic chain runs as follows. German statutory insurance generally does not reimburse weight-loss drugs, so patients already pay out of pocket. That fits the Hims cash-pay subscription model without competing with public insurance for share. It is the third international expansion, after the UK and Hers in Australia (13-14 Oct). The underlying infrastructure is the 2025 Zava acquisition (Zava already operated in Germany), so Hims is grafting its brand and acquisition engine onto an existing compliance and physician network, at a lower marginal cost than starting from zero. Watch the Q3 earnings on 9 Nov for the international revenue mix and management commentary on German pricing and customer acquisition cost (CAC).
Key evidence
- Hims official newsroom ('Introducing Hims in Germany') and Reuters (20 Oct): forhims.de is live, launching with men's weight management.
- Model: online consultations, with every prescription decided by an EU-licensed physician and in-person needs referred to the patient's own doctor.
- Company stance: a 'long-term commitment', positioned as a supplement to the existing healthcare system, not a replacement.
- Market basis cited by the company (Robert Koch Institute data): about 1 in 5 adults are obese and over 60% of men are overweight. Statutory insurance generally does not reimburse weight-loss drugs, so costs are mostly out of pocket. Over 75% of those trying to lose weight go it alone, and 42% are unwilling to discuss their weight with their family doctor.
- Infrastructure: built on the 2025 Zava acquisition (Zava operated in Germany before the deal). Hims is grafting its brand and customer acquisition onto an existing compliance and physician network, at a lower marginal cost than greenfield.
- No drug is mentioned in the release and no pricing is disclosed. Europe largely lacks the US compounded-drug route, so this most likely ships branded GLP-1. Some media say it is via a Novo Nordisk partnership, which is not in the company release and is unverified.
Show 2 more
- Branded-drug reselling has a materially lower gross margin than own-brand compounded drugs. This is the same dynamic that pressed Q2 gross margin down to 64%. Faster international revenue growth could dilute the margin structure further.
- Third international expansion in a week: the UK (13 Oct) and Hers in Australia (14 Oct) preceded Germany (20 Oct).
Catalysts to watch
- 9 Nov: HIMS Q3 2026 earnings. Watch the international revenue mix, the international subscriber count and management commentary on German pricing and customer acquisition cost
- Pending: whether the company discloses its GLP-1 supplier (a Novo Nordisk partnership is rumoured but unverified) and German pricing
- Further launches in European countries via the Zava footprint are the next logical step, and the next primary signals would be France, the Netherlands and Spain
- The US interim peptide policy is under White House review (OIRA). Any ruling moves the picture for US compounded GLP-1, which still dominates the HIMS margin profile
Risks
- Margin dilution from reselling branded drugs: Europe cannot replicate the US compounded economics, and international growth could compress gross margin further from Q2's 64%
- Drug supply and pricing are undisclosed, so the key economics cannot yet be known
- The rumoured Novo Nordisk partnership is unverified by the company and should not be amplified without company confirmation
- Positioning within the German statutory system as a supplement, not a replacement, is a hedge against regulatory backlash, but any shift in German tele-prescription rules would hit directly
- Securities class-action law firm solicitations and the peptide policy submission to OIRA are a diffusion of already-published events, not new catalysts
Sources (4)
- Hims official newsroom (20 Oct): 'Introducing Hims in Germany'
- Reuters (20 Oct): Germany launch coverage
- Robert Koch Institute: German obesity and overweight prevalence data (cited by the company)
- Prior briefs (13 Oct UK, 14 Oct Hers in Australia): the international expansion arc
A brief is a lead for our research, not a verified conclusion or advice.